SCHEMBL3016151

SCHEMBL3016151

COc1ccc(Cl)cc1S(=O)(=O)N1CCN(c2nc(-c3cc(OC)c(OC)c(OC)c3)cs2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
MAPK1 P28482 3/20 0.56
GAA P10253 1/20 0.56
CYP3A4 P08684 2/20 0.56
CYP2C19 P33261 2/20 0.56
CYP2C9 P11712 1/20 0.56
RAB9A P51151 2/20 0.54
KDM4E B2RXH2 2/20 0.54
POLB P06746 2/20 0.54
HPGD P15428 1/20 0.54
MAPT P10636 7/20 0.53
LMNA P02545 3/20 0.53
TSHR P16473 1/20 0.53
RECQL P46063 2/20 0.48
USP2 O75604 1/20 0.48
HSD17B10 Q99714 1/20 0.48
TP53 P04637 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
NPC1 O15118 1/20 0.48
MEN1 O00255 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016927 0.94 ALDH1A1 (0.56) ALDH1A1MAPK1GAACYP3A4CYP2C19
SCHEMBL3009920 0.93 ALDH1A1 (0.56) ALDH1A1MAPK1GAACYP3A4CYP2C19
SCHEMBL3007942 0.92 ALDH1A1 (0.56) ALDH1A1MAPK1GAACYP3A4CYP2C19
SCHEMBL3016726 0.91 MAPT (0.59) ALDH1A1MAPK1CYP3A4CYP2C19CYP2C9
SCHEMBL3011380 0.91 ALDH1A1 (0.57) ALDH1A1MAPK1CYP3A4CYP2C19RAB9A
SCHEMBL3001254 0.91 ALDH1A1 (0.54) ALDH1A1MAPK1GAACYP3A4CYP2C19
SCHEMBL3017528 0.91 MAPT (0.54) ALDH1A1MAPK1GAACYP3A4CYP2C19
SCHEMBL3000407 0.90 MAPT (0.60) ALDH1A1MAPK1CYP3A4CYP2C19CYP2C9
SCHEMBL3016635 0.90 LMNA (0.59) ALDH1A1MAPK1GAACYP3A4CYP2C19
SCHEMBL3009767 0.90 ALDH1A1 (0.57) ALDH1A1MAPK1GAARAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885MAPK1 2767/4885GAA 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.